(Q36967197)

17 August 2017

1 reference

title

Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type (English)

1 reference

17 August 2017

0 references

1 reference

1

Lily P H Yang

1 reference

17 August 2017

2

Gillian M Keating

1 reference

PubMed ID

17927299

17 August 2017

language of work or name

1 reference

1 January 2007

1 reference

17 August 2017

1 reference

17 August 2017

21

1 reference

17 August 2017

11

1 reference

17 August 2017

957-965

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200721110-00007

17 August 2017

0 references

cites work

Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.

1 reference

12 December 2020

The magnitude of dementia occurrence in the world

1 reference

12 December 2020

Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group

1 reference

12 December 2020

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

1 reference

12 December 2020

Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain

1 reference

12 December 2020

Long-term cholinesterase inhibitor treatment of Alzheimer's disease.

1 reference

12 December 2020

Transdermal treatment options for neurological disorders: impact on the elderly

1 reference

12 December 2020

Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease

1 reference

12 December 2020

The primary care of Alzheimer disease

1 reference

12 December 2020

Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles

1 reference

12 December 2020

Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications

1 reference

12 December 2020

Inhibition of human cholinesterases by drugs used to treat Alzheimer disease

1 reference

12 December 2020

Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II--Pharmacologic therapy. Alzheimer's Disease (AD) Managed Care Advisory Council.

1 reference

12 December 2020

Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.

1 reference

12 December 2020

Guidelines for managing Alzheimer's disease: Part II. Treatment.

1 reference

12 December 2020

Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease

1 reference

12 December 2020

Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application

1 reference

12 December 2020

A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase

1 reference

12 December 2020

IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease

1 reference

12 December 2020

Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease.

1 reference

12 December 2020

10.2165/00023210-200721110-00007

Identifiers

DOI

1 reference

PubMed ID

17927299

Dimensions Publication ID

17 August 2017

0 references

1 reference

PubMed ID

17927299